Anton Toutov v. Curative Labs Inc.

CourtDistrict Court, C.D. California
DecidedMarch 20, 2023
Docket2:20-cv-11284
StatusUnknown

This text of Anton Toutov v. Curative Labs Inc. (Anton Toutov v. Curative Labs Inc.) is published on Counsel Stack Legal Research, covering District Court, C.D. California primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Anton Toutov v. Curative Labs Inc., (C.D. Cal. 2023).

Opinion

Case 2:20-cv-11284-ODW-AS Document 148 Filed 03/20/23 Page 1 of 20 Page ID #:5156

O 1

2 3 4 5 6 7

8 United States District Court 9 Central District of California

11 ANTON TOUTOV, Case № 2:20-cv-11284-ODW (ASx)

12 Plaintiff, ORDER DENYING DEFENDANTS’ 13 v. 14 C URATIVE LABS INC. et al., MOTIONS FOR SUMMARY 15 JUDGMENT [87] [110] Defendants.

16 17 I. INTRODUCTION 18 Plaintiff Anton Toutov initiated this action for breach of contract and fiduciary 19 duties regarding his claimed minority ownership of an anti-doping laboratory startup 20 company that ultimately became a very profitable COVID-19 testing company. (See 21 Compl., ECF No. 1.) Defendants move for summary judgment, primarily arguing that 22 Toutov cannot prove he was ever an owner-shareholder of the company and is 23 therefore not entitled to the relief he seeks. (Martin & Scott Mot. Summ. J. (“MS 24 Mot.” or “Martin & Scott Motion”), ECF No. 87; Curative Mot. Summ. J. 25 (“Cur. Mot.” or “Curative Motion”), ECF No. 110.) For the reasons discussed below, 26 the Court DENIES both Motions.1 27

28 1 Having carefully considered the papers filed in connection with the Motions, the Court deemed the matters appropriate for decision without oral argument. Fed. R. Civ. P. 78; C.D. Cal. L.R. 7-15. Case 2:20-cv-11284-ODW-AS Document 148 Filed 03/20/23 Page 2 of 20 Page ID #:5157

1 II. BACKGROUND 2 As it must on a motion for summary judgment, the Court sets forth the material 3 facts, some of which are obviously disputed, and views all reasonable inferences to be 4 drawn from them in the light most favorable to Toutov, the non-moving party. Scott 5 v. Harris, 550 U.S. 372, 378 (2007). Here, the number of material factual disputes is 6 telling from the outset. 7 A. The Company 8 In 2014, Jonathan Martin and Paul Scott founded SA Laboratories Inc. (Martin 9 & Scott Statement of Uncontroverted Facts (“MSUF”) 1–2, ECF No. 87-2; Curative 10 Statement Uncontroverted Facts (“CUF”) 1, ECF No. 110-1.) As of March 2015, SA 11 Laboratories was officially doing business as “Kor’va Labs.” (MSUF 5.) In 12 December 2018, SA Laboratories formally amended its name to KorvaLabs, Inc. 13 (MSUF 21; CUF 18.) In May 2020, KorvaLabs, Inc. again amended its name, this 14 time to Curative Labs Inc. (“CLI”). (MSUF 29; CUF 18.) As discussed below, CLI is 15 now a wholly-owned subsidiary of Curative, Inc. (“Curative”). (CUF 14; Toutov 16 Statement Genuine Disputes re: CUF (“TGDC”) 107, ECF No. 127-1.) For the 17 purposes of this Order, the Court refers to the entity known as SA Laboratories, 18 Kor’va Labs, and CLI as the “Company” or “CLI.” 19 B. The Ownership 20 Martin and Scott assert that the Company was authorized to issue ten million 21 shares of stock, and did issue four million shares each to Scott, the Chief Executive 22 Officer, and to Martin, the Chief Financial and Chief Operating Officer. (CUF 2–3, 23 disputed by TGDC 2–3; MSUF 4 (undisputed re: roles).) Toutov agrees that Martin 24 and Scott each owned 40% of the Company, but contends that he also owns 20% of 25 the equity based on a 2015 oral agreement with Martin and Scott. (Toutov Statement 26 Genuine Disputes re: MSUF (“TGDMS”) 40–41, 43, ECF No. 100-1, disputed in part 27 by Resp. TGDMS 43, ECF No. 103-1; CUF 20–21, 23; TGDC 20–21, 23.) The 28 parties dispute whether the Company issued shares to non-party Robert Tsai for cash

2 Case 2:20-cv-11284-ODW-AS Document 148 Filed 03/20/23 Page 3 of 20 Page ID #:5158

1 and equivalents. (CUF 3, disputed by TGDC 3.) They also dispute whether the 2 Company held annual meetings or maintained a contemporaneous stock ledger. (See 3 MSUF 3, disputed by TGDMS 3; CUF 3–4, disputed by TGDC 3–4.) 4 C. The Agreement 5 The parties agree that, in May 2015, Martin and Scott entered an oral agreement 6 with Toutov concerning a 20% stake in the Company. (MSUF 7; TGDMS 41.) 7 Beyond this, the parties dispute the terms of the agreement. Toutov contends Martin 8 and Scott offered Toutov 20% equity to join the Company, which equity would vest 9 once he completed his Ph.D. and obtained his U.S. Permanent Resident Visa. 10 (TGDMS 7, 43.) Martin and Scott contend they offered Toutov “a conditional 20% 11 stake in [the Company] in exchange for his raising funding and procuring clients,” 12 subject to Martin’s and Scott’s satisfaction. (MSUF 7; Resp. TGDMS 43.) Curative 13 and CLI contend Martin and Scott entered the agreement as individuals, (CUF 20), 14 while Toutov contends Martin and Scott entered the agreement on behalf of the 15 Company, (TGDC 20). 16 In September 2016, Toutov received his Ph.D. in chemistry at Caltech and 17 obtained his U.S. Permanent Resident Card. (MSUF 11; TGDMS 53.) Martin and 18 Scott took Toutov out to dinner to celebrate. (MSUF 11, 14.) Toutov contends the 19 dinner also celebrated the vesting of his 20% ownership interest and his assuming the 20 role of Chief Science Officer. (See TGDMS 11, 14.) At the dinner, Martin and Scott 21 gave Toutov two papers. (MSUF 14.) The first had Toutov’s photo and read “Anton 22 Toutov PhD / Permanent US Citizen,” and the second read “K-Stock Certificate: This 23 certifies that Anton Toutov, PhD is the holder of 25 shares of the 125 shares issued by 24 Korva Labs, Inc.” (MSUF 12–13.) Martin and Scott contend these papers were 25 novelty items; Toutov contends the stock certificate symbolically represented the 26 vesting of his 20% ownership interest in the Company. (MSUF 13, disputed by 27 TGDMS 13.) 28

3 Case 2:20-cv-11284-ODW-AS Document 148 Filed 03/20/23 Page 4 of 20 Page ID #:5159

1 D. Toutov as Owner-Director 2 Toutov contends that, from the time he joined SA Laboratories in 2015 and 3 continuing through 2019, Martin and Scott conducted business and held Toutov out as 4 an owner and director of the Company. For instance, they filed documents with 5 government agencies including: Statements of Information with the California 6 Secretary of State identifying Toutov as a Director or an Owner, (TGDMS 62, 70; 7 TGDC 73, 80); a “Disclosure of Ownership and Control Interest Statement” with the 8 California Health and Human Services Agency, identifying Toutov as an owner, 9 (TGDMS 71; TGDC 78); a business license with the City of San Dimas, adding 10 Toutov’s name to Martin’s and Scott’s, (TGDMS 63; TGDC 75); and “Notification of 11 Laboratory Change” and renewal applications with the California Department of 12 Public Health, identifying Toutov as an owner of the Company, (TGDMS 72–73; 13 TGDC 79). Martin and Scott also represented Toutov as an owner in other ways, 14 including by informing USCIS that Toutov’s position with SA Laboratories was an 15 “equity position,” (TGDMS 49); telling new hires they needed to interview with 16 Toutov, the “third owner,” (TGDMS 56; TGDC 77); and stating in emails to Toutov 17 that “[w]e are all owners of the [C]ompany and will share the burden of [a proposed 18 business] loan,” (TGDMS 77–78; TGDC 81). 19 Martin, Scott, CLI, and Curative contend Toutov was never an owner or 20 shareholder of the Company. (See, e.g., MSUF 25, disputed by TGDMS 25; CUF 38, 21 disputed by TGDC 38.) 22 E. Removal of Toutov & Sale to Curative, Inc. 23 Disputes arose between Martin, Scott, and Toutov with respect to Toutov’s 24 ownership interest and the May 20, 2015 agreement. (See TGDMS 88.) Toutov 25 asserts that his requests for meetings or details about the Company’s finances went 26 largely unanswered. (See TGDMS 75–76, 80, 85.) In August 2019, the Company 27 filed a Statement of Information with the Secretary of State removing Toutov as a 28 director without Toutov’s knowledge. (TGDMS 84; TGDC 83.) In September 2019,

4 Case 2:20-cv-11284-ODW-AS Document 148 Filed 03/20/23 Page 5 of 20 Page ID #:5160

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Anderson v. Liberty Lobby, Inc.
477 U.S. 242 (Supreme Court, 1986)
Scott v. Harris
550 U.S. 372 (Supreme Court, 2007)
Cycalona Gowen v. Tiltware LLC
437 F. App'x 528 (Ninth Circuit, 2011)
R & R Sails, Inc. v. Insurance Co. of Pennsylvania
673 F.3d 1240 (Ninth Circuit, 2012)
Charles Yeager v. Connie Bowlin
693 F.3d 1076 (Ninth Circuit, 2012)
Oasis West Realty v. Goldman
250 P.3d 1115 (California Supreme Court, 2011)
Perata v. Oakland Scavenger Co.
244 P.2d 940 (California Court of Appeal, 1952)
Mesler v. Bragg Management Co.
702 P.2d 601 (California Supreme Court, 1985)
People v. Beber
231 P.2d 516 (California Court of Appeal, 1951)
Brainard v. De La Montanya
116 P.2d 66 (California Supreme Court, 1941)
McLoughlin v. L. Bloom Sons Co., Inc.
206 Cal. App. 2d 848 (California Court of Appeal, 1962)
Californians for Alternatives to Toxics v. Department of Food & Agriculture
38 Cal. Rptr. 3d 638 (California Court of Appeal, 2005)
Teselle v. McLoughlin
173 Cal. App. 4th 156 (California Court of Appeal, 2009)
Tetra Technologies, Inc. v. Harter
823 F. Supp. 1116 (S.D. New York, 1993)

Cite This Page — Counsel Stack

Bluebook (online)
Anton Toutov v. Curative Labs Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/anton-toutov-v-curative-labs-inc-cacd-2023.